Eli Lilly says that it has evidence to show that its amyloid-busting drug solanezumab has a distinct impact on Alzheimer's disease, pointing to a delayed-start 3.5-year extension study, with a group of patients from the original placebo arm continuing to lag behind patients who started on the drug at the beginning.
A cadre of drugmakers is pressing toward late-stage trials with new injectable treatments in the long-stagnant field of migraine therapy, racing to capitalize on what analysts say is a multibillion-dollar market.
With a couple of meds for Type 1 diabetes--the type that's usually diagnosed in children and young adults--in its lineup, Eli Lilly has a vested interest in helping children and their parents understand the disease. And on that front, it's just released a new book to add to a growing collection of kid-friendly materials.
Biogen and Eli Lilly, two drugmakers making big bets in Alzheimer's disease, are set to present clinical data on a pair of much-scrutinized projects with potential to change the industry's approach to the field.
When the American Society of Clinical Oncology unveiled its scheme for assessing the value of cancer drugs, it included some less-than-flattering drug ratings. One of those was for Eli Lilly's Alimta, a lung cancer drug that's been a blockbuster performer for the U.S.-based company.
An FDA advisory panel offered some key though largely lukewarm support for Eli Lilly's experimental lung cancer drug necitumumab. While there was no formal vote for or against approval, committee members weighed the positives and negatives of a drug that showed only a marginal survival advantage for patients--but a big enough plus for patients that has warranted approvals in the past. And on balance, most supported an approval for Lilly during a roundtable discussion.
On Thursday, a team from Eli Lilly will take the hot seats in front of an advisory committee meeting of external FDA experts to make a case for necitumumab, another cancer drug which offers only marginal efficacy for advanced patients with a troubling profile for potentially lethal adverse events. And their odds-on chance of succeeding helps explain why this field has become so popular with drug developers.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Immunocore has added another string to its collaboration with Eli Lilly. The deal is intended to show whether there is value in combining Immunocore's lead T cell receptor-based therapy with galunisertib and merestinib in patients with metastatic cutaneous and uveal melanomas.
Shares in Adocia rose 10% after its Eli Lilly-partnered fast-acting insulin impressed in a small early-phase study. The data position Adocia to push ahead with development of a product that could surpass Lilly's blockbuster fast-acting insulin Humalog in terms of speed and effectiveness.